Cellectar BioSciences
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Employees
- 20
- Market Cap
- -
- Website
- http://www.cellectar.com
- Introduction
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
- Conditions
- High-Grade Glioma
- Interventions
- Drug: CLR 131
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05610891
- Locations
- ๐บ๐ธ
University of Wisconsin, Carbone Cancer Center, Madison, Wisconsin, United States
๐จ๐ฆHospital for Sick Children, Toronto, Ontario, Canada
๐บ๐ธStanford University, Palo Alto, California, United States
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
- Conditions
- DIPGNeuroblastomaEwing SarcomaPediatric Solid TumorPediatric Brain TumorRhabdomyosarcomaOsteosarcomaPediatric Lymphoma
- Interventions
- Drug: CLR 131
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03478462
- Locations
- ๐บ๐ธ
Texas Children's Hospital, Houston, Texas, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐ฆ๐บChildren's Hospital at Westmead, Westmead, New South Wales, Australia
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
- Conditions
- Small Lymphocytic LymphomaLymphoplasmacytic LymphomaWaldenstrom MacroglobulinemiaMultiple MyelomaMarginal Zone LymphomaDiffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaCentral Nervous System Lymphoma
- Interventions
- Drug: Iopofosine I 131 single doseDrug: Iopofosine I 131 multiple doseDrug: Iopofosine I 131 fractionated dose
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02952508
- Locations
- ๐ฌ๐ง
Cellectar Biosciences site, London, United Kingdom
๐น๐ทCellectar Biosciences, Istanbul, Turkey
๐ฎ๐ฑCellectar Biosciences Site, Jerusalem, Israel
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT02278315
- Locations
- ๐บ๐ธ
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
๐บ๐ธMayo Clinic, Jacksonville, Florida, United States
๐บ๐ธLoyola University Medical Center, Maywood, Illinois, United States
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- Drug: I-124-CLR1404
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01898273
- Locations
- ๐บ๐ธ
Ohio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธMoffitt Cancer Center and Research Institute, Tampa, Florida, United States
Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Registration Number
- NCT01778088
- Locations
- ๐บ๐ธ
University of Maryland School of Medicine, Baltimore, Maryland, United States
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
- First Posted Date
- 2011-12-20
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01495663
- Locations
- ๐บ๐ธ
City of Hope National Medical Center, Duarte, California, United States
๐บ๐ธUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
๐บ๐ธGeorgetown University Hospital, Washington, DC, District of Columbia, United States
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
- Conditions
- Hepatitis C
- Interventions
- Drug: NOV-205
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01058512
- Locations
- ๐บ๐ธ
Orlando Immunology Center, Orlando, Florida, United States
๐บ๐ธUMASS Memorial Medical Center, Worcester, Massachusetts, United States
๐บ๐ธMetroWest Medical Center, Framingham, Massachusetts, United States
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
- Conditions
- Hepatitis C
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00372983
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Cellectar Biosciences, Inc.
- Target Recruit Count
- 903
- Registration Number
- NCT00347412
- Locations
- ๐ต๐ฑ
Oddzial Chemioterapii Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Poland
๐ต๐ฑOddzial Gruzlicy I Chorob Pluc I P, Prabuty, Poland
๐ท๐ดInstitute of Oncology, Department of Medical Oncology II, Bucharest, Romania